Below are the points I could grasp from going through concall:
- Whole Pharma industry is going through slowdown, lot of competition in diagnostic industry resulted in some competition to tarson products.
- Maintained guidance of 500 crore revenue in 2025.
As per them this slowdown phase is temporary but not in position to give any short or mid term guidance. - Last 2 quarters have zero covid related revenue while last year has 15-17% covid related revenue.
- Promoting their products internationally through exibition gain 3-4 distributors.
I guess last year Q4 was bumper and had covid related revenues so next quarter would also be sluggish after that we could be having base set for whole year and then can get fair bit of idea.
| Subscribe To Our Free Newsletter |
